Anakinra (Kineret), an antagonist of the interleukin-1 receptor, recently was FDA approved for treatment of rheumatoid arthritis (RA). In this manufacturer-sponsored, double-blind, randomized ...

Recent trials have demonstrated that DMARDs and DMARD combinations slow disease progression and that biological treatments result in rapid and sustained disease control associated with the ...

Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...

THE new adrenocortical steroid prednisone 1 was used in the treatment of 33 patients with rheumatoid arthritis. Among 33 patients with rheumatoid arthritis treated with prednisone, the disease was ...

A new therapy for the most aggressive type of brain cancer can extend patients' survival while cutting the length of ...

London scientists have discovered a way to reverse inflammation and arterial blockages in rheumatoid arthritis, paving the way for better treatments ... as a potential new cause of blood vessel ...

Biologics for rheumatoid arthritis (RA) are generally quick-acting ... Or, your doctor might add the biologic to your current treatment plan. Taking multiple biologics at the same time may ...

Early treatment escalation to biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) following methotrexate (MTX) failure in new-onset rheumatoid arthritis (RA) does not ...

High serum CXCL13 levels are predictive of treatment failure with first-line MTX among patients with early RA.

Now a growing number of experts, as well as new European guidelines, recommend expanding treatment criteria to allow more people with rheumatoid arthritis to take statins. (Prescribing a statin to ...

University of Birmingham researchers have been awarded £3.5 million funding from Johnson & Johnson to investigate mechanisms of response and non-response to biologic and targeted synthetic therapies ...

Opens in a new tab or window Share on X ... for post-baseline variables like drug treatments started during follow-up, nor did it consider RA disease activity. If patients went outside the ...